Publications of Bita DEZFOULIAN
Bookmark and Share    
Full Text
See detailPatient avec un carcinome spinocellulaire cutané localement avancé et métastatique traité par Cemiplimab
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue Médicale de Liège (2019), (74), 1-5

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de ... [more ▼]

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de l’aire ganglionnaire afférente. Malheureusement, certains cas ne sont plus opérables ou accessibles à la radiothérapie et un traitement systémique est alors indiqué. Les chimiothérapies sont peu efficaces et potentiellement toxiques. Une étude récente évaluant l’efficacité et la tolérance du cemiplimab, un antagoniste PD1, dans les cSCC localement avancés et métastasiques démontre une réponse objective confirmée de 49 % et de 47 %, respectivement, avec un maintien de la réponse d’au moins 6 mois de 63 % et de 60 %, respectivement. Nous présentons le cas d’un patient avec un cSCC localement avancé au niveau du front, avec effraction osseuse et adénopathies cervicales, ayant eu de multiples chirurgies et radiothérapies. Il a présenté une réponse partielle au cemiplimab avec un profil de tolérance satisfaisant. [less ▲]

Detailed reference viewed: 79 (7 ULiège)
Full Text
See detailCarcinome spinocellulaire cutané localement avancé et métastatique traité par cemiplimab.
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue medicale de Liege (2019), 74(7-8), 436-440

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes ... [more ▼]

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes. Unfortunately, some cases are no candidates for surgery or radiotherapy and a systemic treatment may be indicated. Chemotherapies are only partially efficacious and associated with potential toxicities. A recent study evaluating the efficacy and tolerance of cemiplimab, a PD1 antagonist for locally advanced and metastatic cSCC demonstrated an objective response rate of 49 % and 47 % for locally advanced and metastatic cSCC, while maintaining a response of at least 6 months of 63 % and 60 %, respectively. We present a clinical case of a patient with a locally advanced cSCC of the forehead with bone resorption and cervical lymphadenopathies. After failure of multiple surgical interventions and radiotherapies, he responded partially to cemiplimab immunotherapy with a good safety profile. [less ▲]

Detailed reference viewed: 168 (15 ULiège)
Full Text
See detailHERPES ZOSTER IN PSORIASIS PATIENTS UNDERGOING TREATMENT WITH BIOLOGICAL AGENTS: PREVALENCE, IMPACT, AND MANAGEMENT CHALLENGES
EL HAYDERI, Lara ULiege; COLSON, Fany ULiege; DEZFOULIAN, Bita ULiege et al

in Psoriasis: Targets and Therapy (2016)

As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several ... [more ▼]

As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several studies and clinical experience provided evidence that the incidence of HZ increases by twofold to threefold in this patient category. The number of severe cases of HZ, with multisegmental, disseminated cutaneous, and/or systemic involvement, is also increased. Concerning psoriasis patients under biologicals, the clinician should be more alert for an eventual HZ event, in particular during the first year of biological treatment, and be aware of the possibility of more severe HZ cases. HZ may also undergo an age-shift toward younger patients. Rapid identification of risk factors for severe HZ, such as severe prodromal pains and/or the presence of satellite lesions, is recommended. The treatment recommendations of HZ in this patient group are identical to the recently published guidelines for the management of HZ. The live attenuated viral vaccine OKA/Merck strain anti-HZ vaccination is recommended before initiating biological treatment in psoriasis patients. The new adjuvanted anti-HZ vaccine will probably also benefit patients while on biological treatment. [less ▲]

Detailed reference viewed: 86 (3 ULiège)
Full Text
See detailUrticaire chronique : comment explorer, expliquer au patient, traiter?
NAFISSA BENHALLA, Keltoum; DEZFOULIAN, Bita ULiege; KEBE, Mariam et al

in Allergologie pratique (2012)

L'urticaire est une pathologie très fréquente car 15 à 20% de la population fait au moins une poussée aigue dans sa vie. L'urticaire chronique (UC) est un motif de consultation plus rare, mais pose des ... [more ▼]

L'urticaire est une pathologie très fréquente car 15 à 20% de la population fait au moins une poussée aigue dans sa vie. L'urticaire chronique (UC) est un motif de consultation plus rare, mais pose des problèmes de diagnostic étiologique conduisant à des bilans exhaustifs et coûteux ainsi que des difficultés de prise en charge. [less ▲]

Detailed reference viewed: 32 (1 ULiège)
Full Text
See detailSeasonal variations in vitamin D levels in melanoma patients: a single-centre prospective pilot comparative study
FAILLA, Valérie ULiege; CAVALIER, Etienne ULiege; EL HAYDERI, Lara ULiege et al

in Journal of the European Academy of Dermatology and Venereology (2012), 26(5), 651-3

BACKGROUND: More than 90% of vitamin D synthesis is dependent on UV exposure. Photosensitive disorders such as lupus erythematosus, protoporphyria and xeroderma require strict sun avoidance, and vitamin D ... [more ▼]

BACKGROUND: More than 90% of vitamin D synthesis is dependent on UV exposure. Photosensitive disorders such as lupus erythematosus, protoporphyria and xeroderma require strict sun avoidance, and vitamin D deficiency has been demonstrated in these patients. Melanoma patients are also instructed to avoid sun exposure and may hence be expected to be vitamin D deficient. MATERIALS AND METHODS: Winter and summer vitamin D levels were compared in a group of melanoma patients (n =61) and age- and phototype-matched controls (n = 53) without photosensitive disorders. RESULTS: Oral supplementary vitamin D intake was reported in 32.7% of the melanoma patients and in 15.1% in the control group. Despite oral supplementation, only 25% of the melanoma patients and the controls presented with vitamin D levels of 30 ng/mL or higher. In non-supplemented subjects in the melanoma and control groups, respectively, mean winter vitamin D levels were below the recommended threshold at 12.6 ng/mL vs. 13.2 ng/mL, respectively, but not statistically different. These values increased significantly in both groups during the summer to 24.6 and 23.8 ng/mL respectively. CONCLUSION: Unexpected, significant increases in vitamin D levels were seen in melanoma patients during summer, suggesting non-adherence with photoprotective measures and reflecting a heliophilic behaviour. Vitamin D supplementation is recommended in melanoma patients during both winter and summer. [less ▲]

Detailed reference viewed: 75 (4 ULiège)
Full Text
See detailLes effets cutanés indésirables des antagonistes du TNF alpha
FAILLA, Valérie ULiege; SABATIELLO, Murielle ULiege; LEBAS, Eglantine ULiege et al

in Revue Médicale de Liège (2012)

The TNF alpha antagonists, including adalimumab, etanercept and infliximab, represent a class of anti-inflammatory and immunosuppressive drugs. Although cutaneous adverse effects are uncomon, they are ... [more ▼]

The TNF alpha antagonists, including adalimumab, etanercept and infliximab, represent a class of anti-inflammatory and immunosuppressive drugs. Although cutaneous adverse effects are uncomon, they are varied. There is no particular risk profile to develop cutaneous adverse effects. The principal acute side effects are injection site reactions and pruritus. The major long term cutaneous side effects are infectious and inflammatory conditions. Neoplastic skin diseases are exceptional. the association with other immunosuppressive agents can increase the risk of developing cutaneous adverse effects. Some adverse effects, such as lupus erythematosus, require immediate withdrawal of the biological treatment, while in other cases temporary withdrawal is sufficient. The majority of the other cutaneous adverse effects can be dealt without interrupting biologic treatment. Preclinical and clinical investigations revealed that the new biologics, aiming IL12/23, IL23 and IL17, present a similar profile of cutaneous adverse effects, although inflammatory skin reactions may be less often encountered compared to TNF alpha antagonists. [less ▲]

Detailed reference viewed: 407 (28 ULiège)
Full Text
See detailCOMPLICATIONS DERMATOLOGIQUES DES TATOUAGES DEFINITIFS ET TEMPORAIRES
CAUCANAS, MARIE; EL HAYDERI, Lara ULiege; LEBAS, Eglantine ULiege et al

in Annales de Dermatologie et de Vénéréologie (2011)

Detailed reference viewed: 149 (15 ULiège)
Full Text
See detailL'image du mois. Association d'une double luxation des articulations interphalangiennes d'un doigt.
Denoël, C.; Fatemi, F.; Debry, R. et al

in Revue Médicale de Liège (2003), 58(2), 63

Detailed reference viewed: 23 (1 ULiège)